A Cephalosporin Prochelator Inhibits New Delhi Metallo-β-lactamase 1 without Removing Zinc
- 8 May 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (5), 1264-1272
- https://doi.org/10.1021/acsinfecdis.0c00083
Abstract
Antibacterial drug resistance is a rapidly growing clinical threat, partially due to expression of beta-lactamase enzymes, which confer resistance to bacteria by hydrolyzing and inactivating beta-lactam antibiotics. The increasing prevalence of metallo-beta-lactamases poses a unique challenge, as currently available beta-lactamase inhibitors target the active site of serine beta-lactamases but are ineffective against the zinc-containing active sites of metallo-beta-lactamases. There is an urgent need for metallo-beta-lactamase inhibitors and antibiotics that circumvent resistance mediated by metallo-beta-lactamases in order to extend the utility of existing beta-lactam antibiotics for treating infection. Here we investigated the antibacterial chelator-releasing prodrug PcephPT (2-((((6R,7R)-2-carboxy-8-oxo-7-(2-phenylacetamido)-5-thia-1-azabicyclo [4.2.0]-oct-2-en-3-yl)methyl)thio) pyridine 1-oxide) as an inhibitor of New Delhi metallo-beta-lactamase 1 (NDM-1). PcephPT is an experimental compound that we have previously shown inhibits growth of beta-lactamase-expressing E. coli using a mechanism that is dependent on both copper availability and beta-lactamase expression. Here, we found that PcephPT, in addition to being a copper-dependent antibacterial compound, inhibits hydrolysis activity of purified NDM-1with an IC50 of 7.6 mu M without removing zinc from the active site and restores activity of the carbapenem antibiotic meropenem against NDM-1-producing E. coli. This work demonstrates that targeting a metal-binding pharmacophore to beta-lactamase-producing bacteria is a promising strategy for inhibition of both bacterial growth and metallo-beta-lactamases.Funding Information
- Division of Graduate Education (DGE 1644868)
- National Institute of General Medical Sciences (GM084176)
- Duke University
This publication has 40 references indexed in Scilit:
- Copper Influences the Antibacterial Outcomes of a β-Lactamase-Activated Prochelator against Drug-Resistant BacteriaACS Infectious Diseases, 2018
- Alternate “Drug” Delivery Utilizing β-Lactam Cores: Syntheses and Biological Evaluation of β-Lactams Bearing Isocyanate PrecursorsThe Journal of Organic Chemistry, 2016
- Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial InfectionsJournal of Medicinal Chemistry, 2016
- Metallo‐β‐lactamase structure and functionAnnals of the New York Academy of Sciences, 2012
- The emerging NDM carbapenemasesTrends in Microbiology, 2011
- Design and synthesis of a β-lactamase activated 5-fluorouracil prodrugBioorganic & Medicinal Chemistry Letters, 2009
- Metallo-β-lactamases: Novel Weaponry for Antibiotic Resistance in BacteriaAccounts of Chemical Research, 2006
- Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling OpportunityChemical Reviews, 2005
- β-Lactamase-Dependent Prodrugs—Recent DevelopmentsTetrahedron, 2000
- A New Cephalosporin with a Dual Mode of ActionAntimicrobial Agents and Chemotherapy, 1976